Bendamustine — Drug Monograph

Brand names: Treanda, Bendeka, Belrapzo

Drug class: Alkylating Agent

Mechanism of Action

Bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechanism is dual: alkylating agent activity (DNA cross-linking via nitrogen mustard moiety) plus antimetabolite activity (purine analog component disrupts DNA repair). This dual mechanism may explain activity in tumors resistant to classical alkylating agents.

FDA Indications

• Chronic lymphocytic leukemia (CLL) — first-line treatment
• Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of rituximab or rituximab-containing regimen

Common Side Effects

• Myelosuppression (neutropenia, lymphopenia, thrombocytopenia)
• Nausea, vomiting, diarrhea
• Fatigue
• Infusion reactions (fever, chills, pruritis)
• Rash
• Elevated liver enzymes

Clinical Pearl

Bendamustine-rituximab (BR) has demonstrated superiority to R-CHOP for indolent NHL (BRIGHT and StiL trials) with a more favorable toxicity profile and less alopecia, making it a preferred first-line regimen for follicular and marginal zone lymphoma. SAFETY: bendamustine induces severe, prolonged CD4+ T-lymphocyte depletion that persists for months after therapy, so PJP/PCP prophylaxis (e.g., TMP-SMX) and herpesvirus prophylaxis (acyclovir or valacyclovir) are highly recommended and standard…

Related Therapies & Mechanisms

• Cyclophosphamide (Cytoxan) — Alkylating Agent · Lymphoma
• Doxorubicin (Adriamycin) — Lymphoma
• Etoposide (VePesid) — Lymphoma
• Methotrexate (Trexall) — Leukemia